



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Antonio Francesco/Campese**
Address(es) Dept. Molecular Medicine, "Sapienza", University of Rome, Viale Regina Elena 291, 00161 - Roma
Telephone(s) Lab/Office +39 06.49255673
Fax(es) +39 06.49255671
E-mail antonello.campese@uniroma1.it
Nationality Italian

Occupational field Med/46 - Technical Sciences of Laboratory Medicine

Work experience

Dates 2015-date
Occupation or position held Associate Professor
Main activities and responsibilities - Main research interests: the role of Notch signaling 1) in the development of T cell acute leukemia/lymphoma; 2) in the generation and function of Myeloid Derived Suppressor Cells;
- Associate Professor of Technical Sciences of Laboratory Medicine at the Faculty of 'Pharmacy and Medicine';
Name and address of employer Dept. of Molecular Medicine, "Sapienza", University of Rome, Viale Regina Elena, 291 – 00161 Roma
Sector University Institution
Dates 2004-2015
Occupation or position held Researcher, Assistant Professor
Main activities and responsibilities - Researcher in Molecular Pathology. Main research interests: the role of Notch signaling 1) in the development of T cell acute leukemia/lymphoma; 2) in the generation and function of regulatory T cells and in the pathogenesis of experimental autoimmune diabetes;
- Assistant Professor of General Pathology at the Faculty of 'Pharmacy and Medicine';
Name and address of employer Dept. of Molecular Medicine, "Sapienza", University of Rome, Viale Regina Elena, 291 – 00161 Roma
Sector University Institution

Education and training

Dates 2002-2003
Title of qualification awarded Post-doctoral fellow
Name and type of organisation providing education and training Harvard Medical School-Dana Farber Cancer Institute, Boston, MA, USA;
Dates 2002
Title of qualification awarded Postgraduate degree
Name and type of organisation providing education and training Postgraduate Specialty School of 'Allergology and Clinic Immunology', Faculty of Medicine and Surgery, University 'La Sapienza' of Rome;

Dates 2001
 Title of qualification awarded PhD degree
 Name and type of organisation providing education and training PhD Doctorate School of Experimental Medicine, Faculty of Medicine and Surgery, University of L'Aquila

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s) English

Self-assessment
 European level (*)

Language

Understanding		Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production	
C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user

(*) [Common European Framework of Reference for Languages](#)

Additional information

Receiving By appointment

Annexes

Scientific Publication

- 1:** Grazioli P, Felli MP, Screpanti I, **Campese AF**. The mazy case of Notch and immunoregulatory cells. *J Leukoc Biol.* 2017 Mar 14. pii: jlb.1VMR1216-505R. doi: 10.1189/jlb.1VMR1216-505R. [Epub ahead of print] Review. **IF 4.126**
- 2:** Franciosa G, Diluvio G, Gaudio FD, Giuli MV, Palermo R, Grazioli P, **Campese AF**, Talora C, Bellavia D, D'Amati G, Besharat ZM, Nicoletti C, Siebel CW, Choy L, Rustighi A, Sal GD, Screpanti I, Checquolo S. Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. *Oncogene.* 2016 Sep 8;35(36):4741-51. doi: 10.1038/onc.2016.5. **IF 7.932**
- 3:** Perli E, Fiorillo A, Giordano C, Pisano A, Montanari A, Grazioli P, **Campese AF**, Di Micco P, Tuppen HA, Genovese I, Poser E, Preziuso C, Taylor RW, Morea V, Colotti G, d'Amati G. Short peptides from leucyl-tRNA synthetase rescue disease-causing mitochondrial tRNA point mutations. *Hum Mol Genet.* 2016 Mar 1;25(5):903-15. doi: 10.1093/hmg/ddv619. **IF 5.985**
- 4:** Verginelli F, Adesso L, Limon I, Alisi A, Gueguen M, Panera N, Giorda E, Raimondi L, Ciarapica R, **Campese AF**, Screpanti I, Stifani S, Kitajewski J, Miele L, Rota R, Locatelli F. Activation of an endothelial Notch1-Jagged1 circuit induces VCAM1 expression, an effect amplified by interleukin-1 β . *Oncotarget.* 2015 Dec 22;6(41):43216-29. doi: 10.18632/oncotarget.6456 **IF 5.008**
- 5:** Pisano A, Preziuso C, Iommarini L, Perli E, Grazioli P, **Campese AF**, Maresca A, Montopoli M, Masuelli L, Sadun AA, d'Amati G, Carelli V, Ghelli A, Giordano C. Targeting estrogen receptor β as preventive therapeutic strategy for Leber's hereditary optic neuropathy. *Hum Mol Genet.* 2015 Dec 15;24(24):6921-31. doi: 10.1093/hmg/ddv396. **IF 5.985**
- 6:** Anastasiadou E, Garg N, Bigi R, Yadav S, Campese AF, Lapenta C, Spada M, Cuomo L, Botta A, Belardelli F, Frati L, Ferretti E, Faggioni A, Trivedi P. Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells. *Int J Cancer.* 2015 Sep 15;137(6):1491-7. doi: 10.1002/ijc.29489. **IF 5.531**
- 7:** Kumar V, Palermo R, Talora C, **Campese AF**, Checquolo S, Bellavia D, Tottone L, Testa G, Miele E, Indraccolo S, Amadori A, Ferretti E, Gulino A, Vacca A, Screpanti I. Notch and NF- κ B signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. *Leukemia.* 2014 Dec;28(12):2324-35. doi: 10.1038/leu.2014.133. **IF 10.431**

- 8:** Puppini C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, **Campese AF**, Boichard A, Lacroix L, Russo D, Filetti S, Damante G. Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. *Endocrine*. 2014 Nov;47(2):528-36. doi: 10.1007/s12020-014-0204-3. **IF 3.878**
- 9:** Cipriani P, Di Benedetto P, Ruscitti P, **Campese AF**, Liakouli V, Carubbi F, Pantano I, Berardicurt O, Screpanti I, Giacomelli R. Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features. *Arthritis Res Ther*. 2014 Sep 24;16(5):442. doi: 10.1186/s13075-014-0442-z. **IF 3.753**
- 10:** **Campese AF**, Grazioli P, de Cesaris P, Riccioli A, Bellavia D, Pelullo M, Padula F, Noce C, Verkhovskaia S, Filippini A, Latella G, Screpanti I, Ziparo E, Starace D. Mouse Sertoli cells sustain de novo generation of regulatory T cells by triggering the notch pathway through soluble JAGGED1. *Biol Reprod*. 2014 Mar 13;90(3):53. doi: 10.1095/biolreprod.113.113803. **IF 3.318**
- 11:** Germani A, Matrone A, Grossi V, Peserico A, Sanese P, Liuzzi M, Palermo R, Murzilli S, **Campese AF**, Ingravallo G, Canettieri G, Tezil T, Simone C. Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38 α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. *Cancer Lett*. 2014 Mar 1;344(1):110-8. doi: 10.1016/j.canlet.2013.10.035. **IF 5.621**
- 12:** Perli E, Giordano C, Pisano A, Montanari A, **Campese AF**, Reyes A, Ghezzi D, Nasca A, Tuppen HA, Orlandi M, Di Micco P, Poser E, Taylor RW, Colotti G, Francisci S, Morea V, Frontali L, Zeviani M, d'Amati G. The isolated carboxy-terminal domain of human mitochondrial leucyl-tRNA synthetase rescues the pathological phenotype of mitochondrial tRNA mutations in human cells. *EMBO Mol Med*. 2014 Feb;6(2):169-82. doi: 10.1002/emmm.201303198. **IF 8.665**
- 13:** Garg N, Po A, Miele E, **Campese AF**, Begalli F, Silvano M, Infante P, Capalbo C, De Smaele E, Canettieri G, Di Marcotullio L, Screpanti I, Ferretti E, Gulino A. microRNA-17-92 cluster is a direct Nanog target and controls neural stem cell through Trp53inp1. *EMBO J*. 2013 Oct 30;32(21):2819-32. doi: 10.1038/emboj.2013.214. **IF 10.748**
- 14:** Cipriani P, Marrelli A, Benedetto PD, Liakouli V, Carubbi F, Ruscitti P, Alvaro S, Pantano I, **Campese AF**, Grazioli P, Screpanti I, Giacomelli R. Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. *Angiogenesis*. 2013 Jul;16(3):595-607. doi: 10.1007/s10456-013-9338-9. **IF 4.410**
- 15:** Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S, Severa M, Coccia EM, Bigi R, Cirone M, Ferretti E, **Campese AF**, Hummel M, Frati L, Presutti C, Faggioni A, Trivedi P. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. *Leukemia*. 2012 Nov;26(11):2343-52. doi: 10.1038/leu.2012.108. **IF 10.164**
- 16:** Palermo R, Checquolo S, Giovenco A, Grazioli P, Kumar V, **Campese AF**, Giorgi A, Napolitano M, Canettieri G, Ferrara G, Schininà ME, Maroder M, Frati L, Gulino A, Vacca A, Screpanti I. Acetylation controls Notch3 stability and function in T-cell leukemia. *Oncogene*. 2012 Aug 16;31(33):3807-17. doi: 10.1038/onc.2011.533. **IF 7.357**
- 17:** Perli E, Giordano C, Tuppen HA, Montopoli M, Montanari A, Orlandi M, Pisano A, Catanzaro D, Caparrotta L, Musumeci B, Autore C, Morea V, Di Micco P, **Campese AF**, Leopizzi M, Gallo P, Francisci S, Frontali L, Taylor RW, d'Amati G. Isoleucyl-tRNA synthetase levels modulate the penetrance of a homoplasmic m.4277T>C mitochondrial tRNA(Ile) mutation causing hypertrophic cardiomyopathy. *Hum Mol Genet*. 2012 Jan 1;21(1):85-100. doi: 10.1093/hmg/ddr440. **IF 7.692**
- 18:** Barbarulo A, Grazioli P, **Campese AF**, Bellavia D, Di Mario G, Pelullo M, Ciuffetta A, Colantoni S, Vacca A, Frati L, Gulino A, Felli MP, Screpanti I. Notch3 and canonical NF-kappaB signaling pathways cooperatively regulate Foxp3 transcription. *J Immunol*. 2011 Jun 1;186(11):6199-206. doi: 10.4049/jimmunol.1002136. **IF 5.778**
- 19:** Giannini E, Lattanzi R, Nicotra A, **Campese AF**, Grazioli P, Screpanti I, Balboni G, Salvadori S, Sacerdote P, Negri L. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. *Proc Natl Acad Sci U S A*. 2009 Aug 25;106(34):14646-51. doi: 10.1073/pnas.0903720106. **IF 9.432**
- 20:** **Campese AF**, Grazioli P, Colantoni S, Anastasi E, Mecarozzi M, Checquolo S, De Luca G, Bellavia D, Frati L, Gulino A, Screpanti I. Notch3 and pTalpha/pre-TCR sustain the in vivo function of naturally occurring regulatory T cells. *Int Immunol*. 2009 Jun;21(6):727-43. doi: 10.1093/intimm/dxp042. **IF 3.403**

- 21:** Talora C, **Campese AF**, Bellavia D, Felli MP, Vacca A, Gulino A, Screpanti I. Notch signaling and diseases: an evolutionary journey from a simple beginning to complex outcomes. *Biochim Biophys Acta*. 2008 Sep;1782(9):489-97. doi: 10.1016/j.bbadis.2008.06.008. Review. **IF 4.579**
- 22:** Bellavia D, Checquolo S, **Campese AF**, Felli MP, Gulino A, Screpanti I. Notch3: from subtle structural differences to functional diversity. *Oncogene*. 2008 Sep 1;27(38):5092-8. doi: 10.1038/onc.2008.230. Review. **IF 7.216**
- 23:** Bellavia D, Mecarozzi M, **Campese AF**, Grazioli P, Talora C, Frati L, Gulino A, Screpanti I. Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. *EMBO J*. 2007 Mar 21;26(6):1670-80. **IF 8.662**
- 24:** **Campese AF**, Garbe AI, Zhang F, Grassi F, Screpanti I, von Boehmer H. Notch1-dependent lymphomagenesis is assisted by but does not essentially require pre-TCR signaling. *Blood*. 2006 Jul 1;108(1):305-10. **IF 10.370**
- 25:** Felli MP, Vacca A, Calce A, Bellavia D, **Campese AF**, Grillo R, Di Giovine M, Checquolo S, Talora C, Palermo R, Di Mario G, Frati L, Gulino A, Screpanti I. PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. *Oncogene*. 2005 Feb 3;24(6):992-1000. PubMed PMID: 15592506. **IF 6.872**
- 26:** Talora C, **Campese AF**, Bellavia D, Pascucci M, Checquolo S, Groppioni M, Frati L, von Boehmer H, Gulino A, Screpanti I. Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. *EMBO Rep*. 2003 Nov;4(11):1067-72. **IF 7.390**
- 27:** Anastasi E*, **Campese AF***, Bellavia D, Bulotta A, Balestri A, Pascucci M, Checquolo S, Gradini R, Lendahl U, Frati L, Gulino A, Di Mario U, Screpanti I. Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. *J Immunol*. 2003 Nov 1;171(9):4504-11. *equally contributor. **IF 6.702**
- 28:** **Campese AF**, Bellavia D, Gulino A, Screpanti I. Notch signalling at the crossroads of T cell development and leukemogenesis. *Semin Cell Dev Biol*. 2003 Apr;14(2):151-7. Review. **IF 4.761**
- 29:** Screpanti I, Bellavia D, **Campese AF**, Frati L, Gulino A. Notch, a unifying target in T-cell acute lymphoblastic leukemia? *Trends Mol Med*. 2003 Jan;9(1):30-5. Review. **IF 9.848**
- 30:** Bellavia D, **Campese AF**, Checquolo S, Balestri A, Biondi A, Cazzaniga G, Lendahl U, Fehling HJ, Hayday AC, Frati L, von Boehmer H, Gulino A, Screpanti I. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. *Proc Natl Acad Sci U S A*. 2002 Mar 19;99(6):3788-93. **IF 10.700**

SIGNATURE
ANTONIO FRANCESCO CAMPESE